Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

REducing Systemic Inflammation With LOw-dose Colchicine to ImproVE Cardiovascular Calcification in Chronic Kidney Disease: A Pilot Randomized Open-Label Trial (RESOLVE-CKD)

30 de outubro de 2026 atualizado por: Jing Chen, University of Texas Southwestern Medical Center

REducing Systemic Inflammation With LOw-dose Colchicine to ImproVE Cardiovascular Calcification in Chronic Kidney Disease: A Pilot Randomized Open-Label Trial (RESOLVE-CKD Trial)

This pilot randomized, open-label, outcome blinded clinical trial is to evaluate the preliminary effects of low-dose Colchicine (LoDoCo) on coronary artery calcification (CAC) progression in adults with chronic kidney disease (CKD) and existing coronary artery calcification. Sixty participants will be randomized 1:1 to received LoDoCo plus usual care or usual care lone and followed for 24 months.

The primary objective is to evaluate the effect of LoDoCo on CAC progression measured by ECG-gates noncontrast cardiac computed tomography (CT). Exploratory outcomes include valvular calcification, bone mineral density, inflammatory, vascular, and miner-bone biomarkers, cognitive function, Alzheimer's disease biomarkers, peripheral arterial disease measures, kidney biomarkers, and participant-reported measures of treatment acceptability, adherence, and adverse effects.

Visão geral do estudo

Status

Ainda não está recrutando

Condições

Intervenção / Tratamento

Descrição detalhada

The investigators will conduct a randomized, open-label, outcome-blinded, clinical trial in 60 adults with chronic kidney disease (CKD) and existing coronary artery calcification (CAC) Agatston scores of ≥100-1000. Participants will be randomized 1:1 to receive low-dose Colchicine (LoDoCo) plus usual care or usual care alone for 24 months.

The primary objective is to evaluate the effect of LoDoCo on CAC progression over 24 months. CAC will be assessed by ECG-gated noncontrast cardiac computed tomography (CT). Outcomes will include Agatston score and calcium volume. The study will estimate variance, baseline-to-follow-up correlations, and other parameters needed to inform future sample size, treatment duration, and endpoint selection.

Exploratory objectives include evaluating the effects of LoDoCo on aortic valve and mitral annular calcification, CT-derived vertebral bone mineral density, inflammatory biomarkers, vascular calcification biomarkers, and miner-bone metabolism biomarkers. Additional exploratory analyses will examine cognitive function, Alzheimer's disease biomarkers, peripheral arterial disease measures including ankle-brachial index (ABI) and toe-brachial index (TBI), and kidney outcomes including albumin-creatine ratio (uACR) and estimated glomerular filtration rate (eGFR).

Participant experience with LoDoCo will also be evaluated through assessment of treatment acceptability, adherence, adverse effects, and barriers and facilitators to study participation and retention.

Participants will be followed at baseline, 6 months, 12 months, 18 months, and 24 months for data collection. Participants assigned to the intervention group will undergo additional safety monitoring, including laboratory assessments, throughout the study period.

Tipo de estudo

Intervencional

Inscrição (Estimado)

60

Estágio

  • Fase 2

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Estude backup de contato

Locais de estudo

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

30 anos a 69 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Men and women aged 30-<70 years of all race/ethnicity groups
  • Chronic kidney disease (CKD) stage 3 (estimated glomerular filtration rate (eGFR) 30 to <60 ml/min/1.73m2) or eGFR ≥60 and Urine albumin-to-creatinine ratio (uACR) ≥ 30 mg/g
  • Cardiac artery calcification (CAC) Agatston score ≥100-1000
  • Ability to provide informed consent.

Exclusion Criteria:

  • Current Colchicine therapy
  • Hepatic disease
  • Established peripheral arterial disease (PAD) defined by self-report or ICD-10 codes
  • Congestive heart failure classified as New York Heart Association (NYHA) Functional class III or IV
  • Uncontrolled atrial fibrillation with resting heart rate > 100 beats/min
  • Dementia defined by self-report or ICD-10 codes (F01-F03)
  • Alzheimer's disease defined by self-report or ICD-10 codes (G30)
  • Any clinically active diagnosed infection requiring systemic antimicrobial therapy, positive microbiologic evidence of infection, or infection-related hospitalization within 30 days prior to study enrollment.
  • Immunosuppression, including the use of immunosuppressive medications
  • Current use of chemotherapy drugs or active cancer
  • Pregnancy/breastfeeding
  • Hospitalized within the past 6 months
  • Allergic/intolerance to colchicine
  • Use of P-glycoprotein (p-gp) inhibitor (such as Verapamil, Quinidine, Amiodarone, Ritonavir, Lopinavir/ritonavir, Saquinavir, Nelfinavir)
  • Use of strong cytochrome P450 3A4 (CYP3A4) inhibitors (such as Ketoconazole, Itraconazole, Posaconazole, Voriconazole, Clarithromycin, Erythromycin)
  • Human immunodeficiency virus (HIV) infection
  • Gout attack ≥ 1 time per year
  • Severe anemia (hemoglobin < 8 g/dl for women and < 9 g/dl for men)
  • eGFR <30 ml/min/1.73m2
  • White blood cell count (WBC) <3.0 x10^9/L
  • Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 x Upper Limit of Normal (ULN)
  • Total bilirubin >2 x ULN
  • Glucose >300mg/dL
  • Uses recreational drugs
  • Participant in other conflict clinical trial
  • Unable to complete the study measurements
  • Unable to undergo to computed tomography (CT)
  • Unsafe to participate in this study per investigator's judgement
  • Unable to read and speak English or Spanish

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Solteiro

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Comparador Ativo: Low-Dose Colchicine (LoDoCo)

Participants will receive low-dose Colchicine (LoDoCo) in addition to usual care.

Intervention group will receive LoDoCo (Colchicine 0.5mg), oral, once daily.

Outros nomes:
  • LoDoCo

Participants will receive usual care according to standard clinical practice and treating physician discretion.

Comparador Ativo: Usual Care

Participants will receive usual care alone.

Participants will receive usual care according to standard clinical practice and treating physician discretion.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Change in Coronary Artery Calcification Agatston Scores
Prazo: Baseline, 12 months, 24 months

Agatston scores (Agatston units) will be measured by ECG-gated non-contrast cardiac computed tomography (CCT) scans following standard cardiac imaging protocols. Coronary artery calcification will be quantified using the Coronary Artery Calcium (CAC) Agatston Score. Scores range from 0 Agatston units (no detectable coronary calcification), 1-99 Agatston units (mild calcification), 100-399 Agatston units (moderate calcification), and ≥400 Agatston units (severe calcification, high atherosclerotic burden). Higher scores indicate greater coronary artery calcification and are associated with worse outcomes.

Baseline, 12 months, 24 months
Change in Coronary Artery Calcification Volume Scores
Prazo: Baseline, 12 months, 24 months

Change in Coronary Artery Calcification volume (mm3) will be measured by ECG-gates non-contrast cardiac computed tomography (CCT) scans following standard cardiac imaging protocols.

Baseline, 12 months, 24 months

Outras medidas de resultado

Medida de resultado
Descrição da medida
Prazo
Exploratory: Change in Aortic Valve Calcification Agatston Scores
Prazo: Baseline, 12 months, 24 months

Agatston scores (Agatston units) will be measured by ECG-gated non-contrast cardiac computed tomography (CCT) scans following standard cardiac imaging protocols. Aortic valve calcification will be quantified using the Agatston Scoring method applied to calcified lesions of the aortic valve. Scores range from 0 Agatston units (no detectable coronary calcification), 1-99 Agatston units (mild calcification), 100-399 Agatston units (moderate calcification), and ≥400 Agatston units (severe calcification, high atherosclerotic burden). Higher scores indicate greater coronary artery calcification and are associated with worse outcomes.

Baseline, 12 months, 24 months
Exploratory: Change in Aortic Valve Calcification Volume Scores
Prazo: Baseline, 12 months, 24 months

Change in Aortic Valve Calcification volume (mm3) will be measured by ECG-gated non-contrast cardiac computed tomography (CCT) scans following standard cardiac imaging protocols.

Baseline, 12 months, 24 months
Exploratory: Change in Mitral Annular Calcification Agatston Scores
Prazo: Baseline, 12 months, 24 months

Agatston scores (Agatston units) will be measured by ECG-gated non-contrast cardiac computed tomography (CCT) scans following standard cardiac imaging protocols. Mitral annular calcification will be quantified using the Agatston Scoring method applied to calcified lesions of the mitral valve annulus. Scores range from 0 Agatston units (no detectable coronary calcification), 1-99 Agatston units (mild calcification), 100-399 Agatston units (moderate calcification), and ≥400 Agatston units (severe calcification, high atherosclerotic burden). Higher scores indicate greater coronary artery calcification and are associated with worse outcomes.

Baseline, 12 months, 24 months
Exploratory: Change in Mitral Annular Calcification Volume Scores
Prazo: Baseline, 12 months, 24 months

Change in Mitral Annular Calcification volume (mm3) will be measured by ECG-gates non-contrast cardiac computed tomography (CCT) scans following standard cardiac imaging protocols.

Baseline, 12 months, 24 months
Exploratory: Change in Vertebral Bone Mineral Density (BMD)
Prazo: Baseline, 12 months, 24 months

Change in vertebral BMD (mg/cm³) will be measured from ECG-gated non-contrast computer tomography (CT) using validated CT-based densitometry methods. BMD will be quantified within the vertebral bodies. Vertebral MBD values range from <80mg/cm³ (very low), 80-120mg/cm³ (low), and >120 mg/cm³ (normal). Lower TBI values are associated with worse outcomes.

Baseline, 12 months, 24 months
Exploratory: Change in C-Reactive Protein (CRP) Levels
Prazo: Baseline, 12 months, 24 months

Circulating CRP (mg/L) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Interleukin-1 beta (IL-1β) Levels
Prazo: Baseline, 12 months, 24 months

Circulating IL-1β levels (pg/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Interleukin-6 (IL-6) Levels
Prazo: Baseline, 12 months, 18 months

Circulating IL-6 levels (pg/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 18 months
Exploratory: Change in Interleukin-18 (IL-18) Levels
Prazo: Baseline, 12 months, 24 months

Circulating IL-18 levels (pg/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Tumor Necrosis Factor alpha
Prazo: Baseline, 12 months, 24 months

Circulating TNF-a levels (pg/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Interleukin-17 (IL-17) Levels
Prazo: Baseline, 12 months, 24 months

Circulating IL-17 levels (pg/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Monocyte Chemoattractant Protein-1 (MCP-1) levels
Prazo: Baseline, 12 months, 24 months

Circulating MCP-1 levels (pg/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Serum Klotho Levels
Prazo: Baseline, 12 months, 24 months

Circulating klotho levels (pg/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Fetuin A Levels
Prazo: Baseline, 12 months, 24 months

Circulating fetuin A levels (ng/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Osteopontin Levels
Prazo: Baseline, 12 months, 24 months

Circulating osteopontin levels (ng/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Bone Morphogenetic Protein-2 (BMP-2) Levels
Prazo: Baseline, 12 months, 24 months

Circulating BMP-2 levels (ng/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Bone Morphogenetic Protein-4 (BMP-4) Levels
Prazo: Baseline, 12 months, 24 months

Circulating BMP-4 levels (ng/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Bone Morphogenetic Protein-7 (BMP-7) Levels
Prazo: Baseline, 12 months, 24 months

Circulating BMP-7 levels (ng/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Serum Phosphate levels
Prazo: Baseline, 12 months, 24 months

Circulating serum phosphate levels (mg/dL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Serum Calcium Levels
Prazo: Baseline, 12 months, 24 months

Circulating serum calcium levels (mg/dL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Parathyroid Hormone (PTH) levels
Prazo: Baseline, 12 months, 24 months

Circulating PTH levels (pg/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Bone-Specific Alkaline Phosphatase (BSAP) Levels
Prazo: Baseline, 12 months, 24 months

Circulating serum BSAP levels (ug/L) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Fibroblast Growth Factor 23 (FGF23) Levels
Prazo: Baseline, 12 months, 24 months

Circulating FGF23 levels (pg/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Wnt Inhibitory Factor-1 Levels
Prazo: Baseline, 12 months, 24 months

Circulating Wnt Inhibitory Factor-1 (pg/dL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Intact N-Terminal Propeptide of Type I Procollagen (P1NP) Levels
Prazo: Baseline, 12 months, 24 months

Circulating P1NP levels (pg/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Sclerostin Levels
Prazo: Baseline, 12 months, 24 months

Circulating sclerostin levels (pg/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Tartrate-Resistant Acid Phosphatase 5b (TRAP-5b) Levels
Prazo: Baseline, 12 months, 24 months

Circulating TRAP-5b levels (U/L) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in National Institutes of Health (NIH) Toolbox Fluid Cognition Composite Standard Score
Prazo: Baseline, 12 months, 24 months

The NIH Toolbox Fluid Cognition Composite score assesses cognitive functions involved in processing and responding to new information, including attention, executive function, episodic memory, processing speed, and working memory. The age-adjusted Fluid Cognition Composite Standard Score is derived from participant performance on NIH Toolbox cognitive assessments and calculated according to NIH Toolbox scoring procedures. Scores are reported as standard scores without physical units, with a normative mean of 100 and standard deviation of 15. Scores of 70 or lower indicate significant impairment, scores around 85 are below average, scores around 100 are average, scores around 115 are above average, and scores around 130 are superior. Higher scores indicate better cognitive performance.

Baseline, 12 months, 24 months
Exploratory: Change in Executive Function
Prazo: Baseline, 12 months, 24 months

Executive function will be assessed using the NIH Toolbox Dimensional Change Card Sort Test. Change in the age-adjusted standard score will be derived from participant performance and calculated according to NIH Toolbox scoring procedures. Scores are reported as standard scores without physical units, with a normative mean of 100 and standard deviation of 15. Higher scores indicating better executive functioning.

Baseline, 12 months, 24 months
Exploratory: Change in Attention/Inhibitory Control
Prazo: Baseline, 12 months, 24 months

Attention and inhibitory control will be assessed using the NIH Toolbox Flanker Inhibitory Control Test. Change in the age-adjusted standard score will be derived from participant performance and calculated according to NIH Toolbox scoring procedures. Scores are reported as standard scores without physical units, with a normative mean of 100 and standard deviation of 15. Higher scores indicating better attention and inhibitory control.

Baseline, 12 months, 24 months
Exploratory: Change in Processing Speed
Prazo: Baseline, 12 months, 24 months

Processing speed will be assessed using the NIH Toolbox Pattern Comparison Processing Speed test. Change in the age-adjusted standard score will be derived from participant performance and calculated according to NIH Toolbox scoring procedures. Scores are reported as standard scores without physical units, with a normative mean of 100 and standard deviation of 15. Higher scores indicating better processing speed.

Baseline, 12 months, 24 months
Exploratory: Change in Working Memory
Prazo: Baseline, 12 months, 24 months

Working memory will be assessed using the NIH Toolbox List Sorting Working Memory Test. Change in the age-adjusted standard score will be derived from participant performance and calculated according to NIH Toolbox scoring procedures. Scores are reported as standard scores without physical units, with a normative mean of 100 and standard deviation of 15. Higher scores indicating better working memory.

Baseline, 12 months, 24 months
Exploratory: Change in Episodic Memory
Prazo: Baseline, 12 months, 24 months

Episodic memory will be assessed using the NIH Toolbox Picture Sequence Memory Test. Change in the age-adjusted standard score will be derived from participant performance and calculated according to NIH Toolbox scoring procedures. Scores are reported as standard scores without physical units, with a normative mean of 100 and standard deviation of 15. Higher scores indicating better episodic memory.

Baseline, 12 months, 24 months
Exploratory: Change in Language/Vocabulary
Prazo: Baseline, 12 months, 24 months

Language/Vocabulary will be assessed using the NIH Toolbox Picture Vocabulary Test and Oral Reading Recognition tests. Change in the age-adjusted standard score will be derived from participant performance and calculated according to NIH Toolbox scoring procedures. Scores are reported as standard scores without physical units, with a normative mean of 100 and standard deviation of 15. Higher scores indicating better language ability.

Baseline, 12 months, 24 months
Exploratory: Change in Southwestern Assessment of Processing Speed (SWAPS) Score
Prazo: Baseline, 12 months, 24 months

The SWAPS will be used to assess processing speed. Change in the normalized T-score will be derived from participant performance and calculated according to SWAPS scoring procedures. Scores are reported as T-scores without physical units, with a normative mean of 50 and standard deviation of 10. Higher scores indicate better processing speed performance.

Baseline, 12 months, 24 months
Exploratory: Change in Texas Card Sorting Test (TCST) Score
Prazo: Baseline, 12 months, 24 months

The TCST will be used to assess executive functioning, including cognitive flexibility and concept formation. Change in the normalized T-score will be derived from participant performance and calculated according to SWAPS scoring procedures. Scores are reported as T-scores without physical units, with a normative mean of 50 and standard deviation of 10. Higher scores indicate better executive functioning.

Baseline, 12 months, 24 months
Exploratory: Change in Phosphorylated tau 217 (p-tau217) levels
Prazo: Baseline, 12 months, 24 months

Circulating p-tau217 levels (pg/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Amyloid-beta 42/40 ratio (Aβ42/40) Levels
Prazo: Baseline, 12 months, 24 months

Circulating Aβ42 and Aβ40 levels (pg/mL) will be measured using standard clinical laboratory assays and the Aβ42/40 ratio calculated from these measurements and reported as a unitless ratio.

Baseline, 12 months, 24 months
Exploratory: Change in Ankle-Brachial Index (ABI)
Prazo: Baseline, 12 months, 24 months

ABI will be measured using semi-automated validated device (simpleABI-600CL). ABI values range from ≤0.90 (Peripheral artery disease), 0.91-0.99 (borderline), 1.00-1.40 (normal).ABI values >1.40 indicate non-compressible arteries, suggestive of arterial stiffness or medial calcification. Both ABI values ≤0.90 and >1.40 are associated with worse outcomes.

Baseline, 12 months, 24 months
Exploratory: Change in Toe-Brachial Index (TBI)
Prazo: Baseline, 12 months, 24 months

TBI will be measured using semi-automated validated device (simpleABI-600CL). TBI values range from ≥0.70 (normal), 0.64-0.69 (borderline), and <0.40-0.50 (severe distal arterial disease/critical ischemia range). TBI values <0.70 is a commonly used threshold suggestive of peripheral artery disease. Lower TBI values are associated with worse outcomes.

Baseline, 12 months, 24 months
Exploratory: Change in Percentage of Participants with Ankle-Brachial Index (ABI) ≤0.9 or >1.4
Prazo: Baseline, 12 months, 24 months

ABI will be measured using semi-automated validated device (simpleABI-600CL). The percentage (%) of participants with an ABI ≤0.9, indicative of peripheral arterial disease, or an ABI >1.4, indicative of non-compressible arteries suggestive of arterial stiffness or medial calcification will be determined. Higher percentages indicate a greater proportion of participants with abnormal ABI findings.

Baseline, 12 months, 24 months
Exploratory: Change in Urine Albumin-to-Creatine Ratio (uACR)
Prazo: Baseline, 12 months, 24 months

Circulating urinary albumin and creatine levels (mg/dL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Estimated Glomerular Filtration Rate (eGFR)
Prazo: Baseline, 12 months, 24 months

eGFR values (mL/min/1.73m2) will be calculated using the NKF-ASN CKD-Epi refit formula.

Baseline, 12 months, 24 months

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Investigador principal: Jing Chen, MD, University of Texas

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Publicações Gerais

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

30 de outubro de 2026

Conclusão Primária (Estimado)

1 de maio de 2029

Conclusão do estudo (Estimado)

1 de maio de 2029

Datas de inscrição no estudo

Enviado pela primeira vez

11 de junho de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

11 de junho de 2026

Primeira postagem (Real)

17 de junho de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

4 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

30 de outubro de 2026

Última verificação

1 de outubro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • STU20260896
  • 99077 (Outro identificador: UT Southwestern Medical Center)

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

IRB approval is required before sharing IPD.

Tipo de informação de suporte de compartilhamento de IPD

  • PROTOCOLO DE ESTUDO
  • SEIVA

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

produto fabricado e exportado dos EUA

Sim

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .